0·5% PRO2000 gel	Placebo gel	HIV-1 incidence	21608	21862	In the primary efficacy analysis, incidence of HIV-1 did not differ between groups at discontinuation of 2% PRO2000 or study end (table 2). Equally, incidence of HIV-1 did not differ between groups in the second analysis that did not censor for pregnancy
0·5% PRO2000 gel	Placebo gel	Gel efficacy in inconsistent gel users	21875	22108	Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87–1·35, p=0·87) and inconsistent (1·17, 0·42–1·72, p=0·42) gel users (p=0·47 for interaction).
0·5% PRO2000 gel	Placebo gel	Gel efficacy in consistent gel users	-1	-1	Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87�??1·35, p=0·87) and inconsistent (1·17, 0·42�??1·72, p=0·42) gel users (p=0·47 for interaction).
0·5% PRO2000 gel	Placebo gel	Gel efficacy in consistent gel users	21875	22108	Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87–1·35, p=0·87) and inconsistent (1·17, 0·42–1·72, p=0·42) gel users (p=0·47 for interaction).
PRO2000 gels	Placebo gel	Adverse events	24191	24266	No deaths or serious adverse events were regarded as related to study gels.
0·5% PRO2000 gel	Placebo gel	HIV-1 incidence	21608	21873	In the primary efficacy analysis, incidence of HIV-1 did not differ between groups at discontinuation of 2% PRO2000 or study end (table 2). Equally, incidence of HIV-1 did not differ between groups in the second analysis that did not censor for pregnancy (table 2).
0·5% PRO2000 gel	Placebo gel	Gel efficacy in inconsistent gel users	-1	-1	Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87�??1·35, p=0·87) and inconsistent (1·17, 0·42�??1·72, p=0·42) gel users (p=0·47 for interaction).
